Company Profile
bioAffinity Technologies, Inc. Stock Price, News & Analysis
- Ticker:
- BIAF
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
0.53 USD (-0.02%)
Close
Last updated: August 6, 2026
7.62M USD
Market cap
Why the stock is moving
The latest monitored company update is “bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung.” The corresponding closing-price reaction is not yet available.
Company overview
Noninvasive Lung Diagnostics
bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples.
CyPath Lung
CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk of lung cancer, including those with indeterminate imaging findings. It is positioned between imaging surveillance and invasive diagnostic procedures. The company is also exploring applications of its cellular-analysis platform in asthma and chronic obstructive pulmonary disease, including potential companion-diagnostic uses.
Future catalysts
bioAffinity’s catalysts are lung-cancer screening adoption and any update that clarifies whether the diagnostics platform can scale. The company still needs a stronger commercial runway.
Recent news
- 01
bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
Source: bioAffinity Technologies, Inc.
- 02
- 03
bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
Source: bioAffinity Technologies, Inc.
- 04
bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
Source: bioAffinity Technologies, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of bioAffinity Technologies, Inc. (BIAF)?
bioAffinity Technologies, Inc. (BIAF) most recently closed at 0.53 USD, a -0.02% move versus the previous session.
What is the market cap of bioAffinity Technologies, Inc. (BIAF)?
bioAffinity Technologies, Inc. currently has a market capitalization of 7.62M USD on BioPharmSignal.
What does bioAffinity Technologies, Inc. do?
Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease. Its approach uses flow-cytometry and artificial-intelligence analysis of cells collected from sputum samples. CyPath Lung CyPath Lung is a laboratory-developed test intended to help assess patients at elevated risk...
On which exchange is BIAF stock listed?
bioAffinity Technologies, Inc. (BIAF) is associated with NASDAQ, United States, MedTech.
What is Noninvasive?
Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease.
Which conditions is bioAffinity Technologies, Inc. targeting with Noninvasive?
bioAffinity Technologies, Inc. is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does bioAffinity Technologies, Inc. describe recent progress with Noninvasive?
bioAffinity’s catalysts are lung-cancer screening adoption and any update that clarifies whether the diagnostics platform can scale. The company still needs a stronger commercial runway.
What is Lung?
Noninvasive Lung Diagnostics bioAffinity Technologies develops noninvasive tests for the early detection and characterization of lung disease.